Turnstone Biologics Corp. (NASDAQ: TSBX) had its price target lowered by analysts at Piper Sandler from $20.00 to $3.75. They now have an "overweight" rating on the stock.
Turnstone Biologics Corp. (NASDAQ: TSBX) had its price target lowered by analysts at Bank of America Co. from $12.00 to $10.00. They now have a "buy" rating on the stock.
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer [Yahoo! Finance]
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer